drugset / Trial / NCT04454489
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
Phase 2
Completed
21 enrolled
Wake Forest University Health Sciences
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, non-randomized pilot study to evaluate the efficacy and tolerability of combination quad-shot palliative radiotherapy with immunotherapy for advanced/recurrent/metastatic head and neck cancer.
Timeline
- Start
- 2021-02-25
- Primary completion
- 2025-02-18
- Completion
- 2025-04-30
Publications
- Hughes RT, Smith S, Lycan TW Jr, Bunch PM, D'Agostino RB Jr, Frizzell BA, Kinney RD, Rashid S, Triozzi P, Zhang W, Furdui CM, Porosnicu M. Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer: A Nonrandomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2026 Jun 18:e261527. doi: 10.1001/jamaoto.2026.1527. Online ahead of print.
- Hughes RT, Gebeyehu RR, Kalada JM, Lycan TW, Frizzell BA, Kinney RD, D'Agostino RB, Bunch PM, Triozzi P, Zhang W, Furdui CM, Porosnicu M. Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer. Future Oncol. 2023 Jul;19(22):1523-1534. doi: 10.2217/fon-2022-1146. Epub 2023 May 18.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |